Form 4: BioAffinity Technologies Executive Chairman Steven Girgenti Reports Acquisition of Shares

Steven Girgenti, Executive Chairman of bioAffinity Technologies, reports acquiring shares of common stock and holding shares indirectly through a trust.

Summary

• On June 12, 2024, Steven Girgenti, the Executive Chairman of bioAffinity Technologies, acquired 8,296 shares of common stock.
• These shares were granted as restricted stock and vested immediately at a price of $0.00.
• Following this transaction, Girgenti directly owns 1,031,464 shares of common stock.
• Girgenti also indirectly owns 8,955 shares through the Cranye Girgenti Testamentary Trust, for which he serves as co-trustee.
• He disclaims beneficial ownership of these shares except to the extent of his pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock acquisition by an executive. The acquisition itself could be seen as mildly positive, but the document is primarily informational.

Positives

• The acquisition of shares by the Executive Chairman could be seen as a positive signal, indicating confidence in the company's future.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders reporting transactions in their company's stock. It provides transparency to the market regarding insider activity.

Stakeholder Impact

• Shareholders are informed about the Executive Chairman's recent stock acquisition.
• This information can influence investor sentiment and potentially affect the stock price.

Key Dates

Keywords

bioAffinity Technologies, Steven Girgenti, BIAF, share acquisition, Form 4, beneficial ownership, restricted stock, Cranye Girgenti Testamentary Trust